MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 522573 | Name: FK3311
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

FK3311 is a cyclooxygenase-2 (COX-2) inhibitor. FK3311 has protective effects on hepatic ischemia-reperfusion injury stemming from the marked inhibition of TxA2. Ischemia-reperfusion injury is induced by activation of the arachidonic acid cascade following the induction of cyclooxygenase-2.

Chemical Structure

FK3311
FK3311
CAS#116686-15-8

Theoretical Analysis

MedKoo Cat#: 522573

Name: FK3311

CAS#: 116686-15-8

Chemical Formula: C15H13F2NO4S

Exact Mass: 341.0533

Molecular Weight: 341.33

Elemental Analysis: C, 52.78; H, 3.84; F, 11.13; N, 4.10; O, 18.75; S, 9.39

Price and Availability

Size Price Availability Quantity
100mg USD 950.00 2 Weeks
200mg USD 1,650.00 2 Weeks
500mg USD 2,450.00 2 Weeks
1g USD 3,450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
FK-3311; FK 3311; FK3311; COX-2 Inhibitor V
IUPAC/Chemical Name
N-(4-acetyl-2-(2,4-difluorophenoxy)phenyl)methanesulfonamide
InChi Key
DIIYLGZNZGPXRR-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H13F2NO4S/c1-9(19)10-3-5-13(18-23(2,20)21)15(7-10)22-14-6-4-11(16)8-12(14)17/h3-8,18H,1-2H3
SMILES Code
CS(=O)(NC1=CC=C(C(C)=O)C=C1OC2=CC=C(F)C=C2F)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 341.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Oshima K, Yabata Y, Yoshinari D, Takeyoshi I. The effects of cyclooxygenase (COX)-2 inhibition on ischemia-reperfusion injury in liver transplantation. J Invest Surg. 2009 Jul-Aug;22(4):239-45. PubMed PMID: 19842898. 2: Otani Y, Takeyoshi I, Yoshinari D, Matsumoto K, Morishita Y. Effects of the COX-2 inhibitor FK3311 on ischemia - reperfusion injury in the rat lung. J Invest Surg. 2007 May-Jun;20(3):175-80. PubMed PMID: 17613692. 3: Kobayashi M, Takeyoshi I, Kurabayashi M, Matsumoto K, Morishita Y. The effects of a cyclooxygenase-2 inhibitor, FK3311, on total hepatic ischemia-reperfusion injury of the rat. Hepatogastroenterology. 2007 Mar;54(74):522-6. PubMed PMID: 17523312. 4: Oshima K, Takeyoshi I, Tsutsumi H, Mohara J, Ohki S, Koike N, Nameki T, Matsumoto K, Morishita Y. Inhibition of cyclooxygenase-2 improves cardiac function following long-term preservation. J Surg Res. 2006 Oct;135(2):380-4. Epub 2006 May 19. PubMed PMID: 16713604. 5: Kawata K, Takeyoshi I, Iwanami K, Sunose Y, Tsutsumi H, Ohwada S, Matsumoto K, Morishita Y. The effects of a selective cyclooxygenase-2 inhibitor on small bowel ischemia-reperfusion injury. Hepatogastroenterology. 2003 Nov-Dec;50(54):1970-4. PubMed PMID: 14696445. 6: Sunose Y, Takeyoshi I, Tsutsumi H, Ohwada S, Oriuchi N, Matsumoto K, Morishita Y. Effect of a cyclooxygenase-2 inhibitor, FK3311, in a canine lung transplantation model. Ann Thorac Surg. 2001 Oct;72(4):1165-71; discussion 1171-2. PubMed PMID: 11603431. 7: Takeyoshi I, Sunose Y, Iwazaki S, Tsutsumi H, Aiba M, Kasahara M, Ohwada S, Matsumoto K, Morishita Y. The effect of a selective cyclooxygenase-2 inhibitor in extended liver resection with ischemia in dogs. J Surg Res. 2001 Sep;100(1):25-31. PubMed PMID: 11516201. 8: Sunose Y, Takeyoshi I, Ohwada S, Tsutsumi H, Iwazaki S, Kawata K, Kawashima Y, Kasahara M, Matsumoto K, Morishita Y. Selective cyclooxygenase-2 inhibitor ameliorates warm ischemia-reperfusion injury of the canine liver. Transplant Proc. 2001 Feb-Mar;33(1-2):862. PubMed PMID: 11267104. 9: Sunose Y, Takeyoshi I, Ohwada S, Tsutsumi H, Iwazaki S, Kawata K, Kawashima Y, Tomizawa N, Matsumoto K, Morishita Y. The effect of cyclooxygenase-2 inhibitor FK3311 on ischemia-reperfusion injury in a canine total hepatic vascular exclusion model. J Am Coll Surg. 2001 Jan;192(1):54-62. PubMed PMID: 11192923. 10: Sunose Y, Takeyoshi I, Tsutsumi H, Kawata K, Tokumine M, Iwazaki S, Tomizawa N, Ohwada S, Matsumoto K, Morishita Y. Effects of FK3311 on pulmonary ischemia-reperfusion injury in a canine model. J Surg Res. 2001 Feb;95(2):167-73. PubMed PMID: 11162041. 11: Kasahara M, Takeyoshi I, Ohwada S, Sunose Y, Iwazaki S, Aiba M, Tomizawa N, Tsutsumi H, Kawashima Y, Ogawa T, Kawate S, Matsumoto K, Morishita Y. Effect of FK3311 on ischemia-reperfusion injury in canine pulmonary models. Transplant Proc. 2000 Nov;32(7):2430-1. PubMed PMID: 11120230. 12: Takeyoshi I, Sunose Y, Iwazaki S, Tsutsumi H, Aiba M, Tomizawa N, Kawashima Y, Kasahara M, Kawate S, Ogawa T, Ohwada S, Matsumoto K, Morishita Y. The effect of cyclooxygenase 2 inhibitor (FK3311) on ischemia-reperfusion injury with hepatectomy in dogs. Transplant Proc. 2000 Nov;32(7):2322-3. PubMed PMID: 11120183. 13: Tsuji K, Nakamura K, Konishi N, Tojo T, Ochi T, Senoh H, Matsuo M. Studies on anti-inflammatory agents. IV. Synthesis and pharmacological properties of 1,5-diarylpyrazoles and related derivatives. Chem Pharm Bull (Tokyo). 1997 Jun;45(6):987-95. PubMed PMID: 9214705. 14: Nakamura K, Ochi T, Matsuo M. [Stereoselective synthesis and pharmacological properties of metabolites of new antiinflammatory agent. 4'-Acetyl-2'-(2,4-difluorophenoxy)methanesulfonanilide (FK3311)]. Yakugaku Zasshi. 1995 Nov;115(11):928-36. Japanese. PubMed PMID: 8568636. 15: Nakamura K, Tsuji K, Konishi N, Matsuo M. Studies on antiinflammatory agents. III. Synthesis and pharmacological properties of metabolites of 4'-acetyl-2'-(2,4-difluorophenoxy)methanesulfonanilide (FK3311). Chem Pharm Bull (Tokyo). 1993 Nov;41(11):2050-2. PubMed PMID: 8293528.

View History

FK-330

FK-330